# Catalyst Pharmaceuticals, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Catalyst Pharmaceuticals, Inc).

## Overview

Catalyst Pharmaceuticals, Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. The company currently markets three prescription products: FIRDAPSE® for Lambert-Eaton myasthenic syndrome, AGAMREE® for Duchenne muscular dystrophy, and FYCOMPA® for epilepsy. Its business model combines in-licensing and commercialization of approved orphan drugs with selective business development for additional rare-disease assets. Catalyst relies heavily on specialty distribution, patient support services, and reimbursement navigation to make small patient populations commercially viable. The company is also using its commercial infrastructure to expand into additional rare-disease opportunities in the U.S. and selected international markets.

## Products & services

• FIRDAPSE® (amifampridine) for LEMS
• AGAMREE® (vamorolone) for Duchenne muscular dystrophy
• FYCOMPA® (perampanel) epilepsy product rights
• Catalyst Pathways® patient support program
• Specialty pharmacy distribution and reimbursement support
• Medical science liaison and field education support

- **Commercial rare-disease medicines** (100%) — Approved prescription drugs sold in the U.S. and through select partners for rare neurology and orphan indications.
- **Patient access and support services** (0%) — Services that help patients and prescribers navigate dosing, reimbursement, and specialty pharmacy fulfillment.
- **Business development and licensing** (0%) — Acquisition or in-licensing of additional rare-disease assets to broaden the product portfolio.

- FIRDAPSE® (amifampridine) for Lambert-Eaton myasthenic syndrome
- AGAMREE® (vamorolone) for Duchenne muscular dystrophy
- FYCOMPA® (perampanel) epilepsy product rights
- Catalyst Pathways® patient support and access program
- Specialty pharmacy distribution for ultra-orphan therapies
- Reimbursement navigation and insurance support services
- Medical education and field-based support for rare disease prescribers

## Customers

Catalyst sells primarily to patients through physicians, specialty pharmacies, and payors rather than to mass-market consumers. Its core customers are neurologists, pediatric specialists, and other prescribers treating rare diseases such as LEMS and Duchenne muscular dystrophy, because these clinicians drive diagnosis, prescribing, and long-term therapy management. Third-party payors and pharmacy benefit managers are also critical customers in practice, since reimbursement and formulary access determine whether patients can start and stay on therapy. The company also serves patients and caregivers directly through Catalyst Pathways®, which helps with education, titration, and access barriers that are especially important in ultra-orphan diseases. For FYCOMPA®, the customer base is broader epilepsy care, but the product is still sold through the same reimbursement-heavy specialty pharmaceutical channel.

- **Rare disease patients** (primary) — Patients with LEMS, Duchenne muscular dystrophy, and epilepsy who need long-term specialty medicines and support to remain on therapy.
- **Prescribing physicians and specialists** (primary) — Neurologists, pediatric specialists, and other clinicians who initiate therapy and manage dosing, titration, and follow-up.
- **Third-party payors and insurers** (primary) — Commercial and public payors that determine reimbursement, prior authorization, and patient out-of-pocket access.
- **Specialty pharmacies** (secondary) — Exclusive dispensing partners that fulfill prescriptions and coordinate access for ultra-orphan products.
- **International licensees and partners** (secondary) — Partners such as KYE and DyDo that commercialize selected products in Canada and Japan.

- Patients with rare neuromuscular diseases who need chronic therapy
- Neurologists and specialists who diagnose and prescribe orphan drugs
- Third-party payors that control reimbursement and access
- Specialty pharmacies that dispense ultra-orphan medicines
- Caregivers and families who need dosing and support guidance
- Hospital/clinic oncology teams for LEMS patients with cancer

## Geography

Catalyst is anchored in the United States, which management describes as the cornerstone of its commercial strategy and where nearly all reported product revenue is generated. The company also has selective international exposure through partners, including Canada for FIRDAPSE® and Japan for FIRDAPSE®, with AGAMREE® being evaluated for Canadian commercialization. This makes the business primarily U.S.-driven, but with some partner-led geographic diversification that can extend product life cycles and broaden the addressable market. Geography matters because the company depends on local regulatory approvals, reimbursement systems, and supply arrangements in each market. It also faces cross-border sourcing and tariff exposure because active ingredients and finished products are obtained from both U.S. and foreign suppliers.

- U.S. is the main commercial market and revenue base
- Canada is a partner market for FIRDAPSE® and potential AGAMREE® launch
- Japan became a partner market for FIRDAPSE® in 2025
- International sales are mostly partner-led rather than direct
- Foreign sourcing of APIs and finished goods creates tariff exposure
- Commercial success depends on local reimbursement and approval pathways

## Strategy

Catalyst's strategy is to maximize the value of its current orphan-drug portfolio while adding new rare-disease assets through licensing or acquisition. Management is prioritizing clinically differentiated, de-risked opportunities with established proof of concept, which fits the company's commercial-stage infrastructure and reduces development risk relative to early-stage biotech. The company is also investing in product-specific field teams, patient support, and medical education to improve uptake and persistence for FIRDAPSE® and AGAMREE®. Internationally, Catalyst is using partners to expand reach without building a large direct-sales footprint outside the U.S. The broader goal is to diversify revenue beyond a small number of products and reduce dependence on any single asset or exclusivity window.

- **Portfolio expansion through licensing and acquisitions** (medium-term) — Reduces concentration risk and extends growth beyond the current three-product base.
- **Commercial optimization of FIRDAPSE® and AGAMREE®** (short-term) — These products are the core growth engines and require strong access, education, and persistence.
- **International partner expansion** (medium-term) — Partner-led launches can broaden reach with limited capital intensity.

- Broaden the rare-disease portfolio through in-licensing and acquisitions
- Focus on clinically differentiated, de-risked assets with proof of concept
- Strengthen commercial execution for FIRDAPSE® and AGAMREE®
- Use specialty support services to improve access and adherence
- Expand internationally through partners rather than heavy direct investment
- Diversify revenue away from dependence on a few orphan products

## Risks

Catalyst's biggest business risk is dependence on successful commercialization of a small number of orphan products, where patient populations are limited and market share must be high to support economics. Access and reimbursement are critical because physicians and patients may want the therapy, but payor coverage, prior authorization, and pricing policies determine actual uptake. The company also faces patent, exclusivity, and generic-entry risk, especially for FIRDAPSE®, where litigation and the timing of exclusivity expiration can materially affect future revenue. Supply-chain and tariff exposure is meaningful because the company sources APIs and finished products from both U.S. and foreign suppliers and has long-term third-party supply commitments. More broadly, rare-disease pharma companies face regulatory, reimbursement, and competitive risks, plus the possibility that acquisitions or in-licensing efforts do not produce value.

- **Loss of exclusivity and generic competition for FIRDAPSE®** [high] — The product's economics depend on patent protection and regulatory exclusivity; generic entry would pressure pricing and volume.
- **Reimbursement and pricing pressure** [high] — Rare-disease products require payor coverage and favorable pricing to achieve meaningful uptake in small populations.
- **Supply-chain disruption and tariffs** [medium] — APIs and finished goods are sourced from U.S. and foreign suppliers, and tariffs could increase costs or delay supply.
- **Business development execution risk** [medium] — The company is pursuing acquisitions and in-licensing, but there is no assurance it can secure value-creating assets.

- Commercial dependence on a small number of orphan drugs
- Payor reimbursement and pricing pressure can limit access
- Patent and exclusivity loss could trigger generic competition
- Litigation over FIRDAPSE® intellectual property is ongoing
- Tariffs and foreign sourcing can raise costs or disrupt supply
- Business development deals may fail to create value
- Small patient populations make demand and pricing less predictable

## Accounting

Catalyst's reported results are heavily influenced by revenue recognition for product sales, including gross-to-net deductions such as rebates and other variable consideration. Because the company sells specialty orphan drugs through a limited distribution network, quarterly revenue can move materially with prescription timing, reimbursement delays, and inventory dynamics at wholesalers and specialty pharmacies. The company also highlights valuation of intangible assets, which is important because acquired product rights can require impairment testing if sales or exclusivity assumptions weaken. Stock-based compensation and valuation allowances for deferred tax assets are also judgmental areas that can affect reported earnings without changing cash generation. Investors should also watch purchase commitments and milestone obligations tied to licensed products, since these can create future cash outflows and accounting complexity.

- **Revenue recognition and gross-to-net reserves** — Affects reported product sales and quarterly comparability
- **Intangible asset valuation and impairment** — Can create non-cash impairment charges
- **Stock-based compensation** — Affects operating margin and net income
- **Deferred tax asset valuation allowance** — Can materially affect tax expense and earnings

- Revenue recognition depends on gross-to-net deductions and rebate estimates
- Quarterly sales can fluctuate with specialty pharmacy and payor timing
- Intangible asset valuation is important for acquired product rights
- Stock-based compensation affects operating expense and reported profit
- Deferred tax asset valuation allowance depends on future taxable income
- License milestones and supply commitments affect future cash obligations

---

*Last updated: 2026-09-24T11:11:02.051541+00:00*